APO Research
Talk to an analyst

APO RESEARCH · REPORT

9-valent HPV Vaccine (9vHPV)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global 9-valent HPV Vaccine (9vHPV) Market Analysis and Forecast 2026-2032

19 December 2025190 pages

Choose your research edition.

Industry Research9-valent HPV Vaccine (9vHPV) Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal 9-valent HPV Vaccine (9vHPV) Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal 9-valent HPV Vaccine (9vHPV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 9-valent HPV Vaccine (9vHPV) Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal 9-valent HPV Vaccine (9vHPV) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global 9-valent HPV Vaccine (9vHPV) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for 9-valent HPV Vaccine (9vHPV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for 9-valent HPV Vaccine (9vHPV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for 9-valent HPV Vaccine (9vHPV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for 9-valent HPV Vaccine (9vHPV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of 9-valent HPV Vaccine (9vHPV) include GSK, Merck and Beijing Wantai Biology Pharmaceutical Industry Limited, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for 9-valent HPV Vaccine (9vHPV), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of 9-valent HPV Vaccine (9vHPV), also provides the revenue of main regions and countries. Of the upcoming market potential for 9-valent HPV Vaccine (9vHPV), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the 9-valent HPV Vaccine (9vHPV) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global 9-valent HPV Vaccine (9vHPV) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for 9-valent HPV Vaccine (9vHPV) revenue, projected growth trends, production technology, application and end-user industry.

9-valent HPV Vaccine (9vHPV) Segment by Company

GSK

Merck

Beijing Wantai Biology Pharmaceutical Industry Limited

9-valent HPV Vaccine (9vHPV) Segment by Type

9—14

15—19

20—45

9-valent HPV Vaccine (9vHPV) Segment by Application

Men

Women

9-valent HPV Vaccine (9vHPV) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 9-valent HPV Vaccine (9vHPV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 9-valent HPV Vaccine (9vHPV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 9-valent HPV Vaccine (9vHPV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of 9-valent HPV Vaccine (9vHPV) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of 9-valent HPV Vaccine (9vHPV) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, 9-valent HPV Vaccine (9vHPV) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global 9-valent HPV Vaccine (9vHPV) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 9—14 Major Player Table 3. 15—19 Major Player Table 4. 20—45 Major Player Table 5. Global 9-valent HPV Vaccine (9vHPV) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Men Major Player Table 7. Women Major Player Table 8. 9-valent HPV Vaccine (9vHPV) Industry Trends Table 9. 9-valent HPV Vaccine (9vHPV) Industry Drivers Table 10. 9-valent HPV Vaccine (9vHPV) Industry Opportunities and Challenges Table 11. 9-valent HPV Vaccine (9vHPV) Industry Restraints Table 12. Global 9-valent HPV Vaccine (9vHPV) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global 9-valent HPV Vaccine (9vHPV) Market Size by Region (2021-2026) & (US$ Million) Table 14. Global 9-valent HPV Vaccine (9vHPV) Market Share by Region (2021-2026) Table 15. Global 9-valent HPV Vaccine (9vHPV) Market Size by Region (2027-2032) & (US$ Million) Table 16. Global 9-valent HPV Vaccine (9vHPV) Market Share by Region (2027-2032) Table 17. Global 9-valent HPV Vaccine (9vHPV) Revenue by Players (US$ Million) & (2021-2026) Table 18. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Players (2021-2026) Table 19. Global 9-valent HPV Vaccine (9vHPV) Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global 9-valent HPV Vaccine (9vHPV) Key Players Headquarters & Area Served Table 21. Global 9-valent HPV Vaccine (9vHPV) Players, Product Type & Application Table 22. Global 9-valent HPV Vaccine (9vHPV) Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global 9-valent HPV Vaccine (9vHPV) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global 9-valent HPV Vaccine (9vHPV) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026) & (US$ Million) Table 27. Global 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032) & (US$ Million) Table 28. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Type (2021-2026) Table 29. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Type (2027-2032) Table 30. Global 9-valent HPV Vaccine (9vHPV) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026) & (US$ Million) Table 32. Global 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032) & (US$ Million) Table 33. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Application (2021-2026) Table 34. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Application (2027-2032) Table 35. GSK Company Information Table 36. GSK Business Overview Table 37. GSK 9-valent HPV Vaccine (9vHPV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. GSK 9-valent HPV Vaccine (9vHPV) Product Portfolio Table 39. GSK Recent Development Table 40. Merck Company Information Table 41. Merck Business Overview Table 42. Merck 9-valent HPV Vaccine (9vHPV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Merck 9-valent HPV Vaccine (9vHPV) Product Portfolio Table 44. Merck Recent Development Table 45. Beijing Wantai Biology Pharmaceutical Industry Limited Company Information Table 46. Beijing Wantai Biology Pharmaceutical Industry Limited Business Overview Table 47. Beijing Wantai Biology Pharmaceutical Industry Limited 9-valent HPV Vaccine (9vHPV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Beijing Wantai Biology Pharmaceutical Industry Limited 9-valent HPV Vaccine (9vHPV) Product Portfolio Table 49. Beijing Wantai Biology Pharmaceutical Industry Limited Recent Development Table 50. North America 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026) & (US$ Million) Table 51. North America 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032) & (US$ Million) Table 52. North America 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026) & (US$ Million) Table 53. North America 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032) & (US$ Million) Table 54. North America 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 55. North America 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021-2026) & (US$ Million) Table 56. North America 9-valent HPV Vaccine (9vHPV) Revenue by Country (US$ Million) & (2027-2032) Table 57. Europe 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026) & (US$ Million) Table 58. Europe 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032) & (US$ Million) Table 59. Europe 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026) & (US$ Million) Table 60. Europe 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032) & (US$ Million) Table 61. Europe 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 62. Europe 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021-2026) & (US$ Million) Table 63. Europe 9-valent HPV Vaccine (9vHPV) Revenue by Country (US$ Million) & (2027-2032) Table 64. China 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026) & (US$ Million) Table 65. China 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032) & (US$ Million) Table 66. China 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026) & (US$ Million) Table 67. China 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032) & (US$ Million) Table 68. Asia 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026) & (US$ Million) Table 69. Asia 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032) & (US$ Million) Table 70. Asia 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026) & (US$ Million) Table 71. Asia 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032) & (US$ Million) Table 72. Asia 9-valent HPV Vaccine (9vHPV) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Asia 9-valent HPV Vaccine (9vHPV) Revenue by Region (US$ Million) & (2021-2026) Table 74. Asia 9-valent HPV Vaccine (9vHPV) Revenue by Region (US$ Million) & (2027-2032) Table 75. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026) & (US$ Million) Table 76. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032) & (US$ Million) Table 77. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026) & (US$ Million) Table 78. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032) & (US$ Million) Table 79. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021-2026) & (US$ Million) Table 81. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Country (US$ Million) & (2027-2032) Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. 9-valent HPV Vaccine (9vHPV) Image Figure 2. Global 9-valent HPV Vaccine (9vHPV) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global 9-valent HPV Vaccine (9vHPV) Market Size Share 2021 VS 2025 VS 2032 Figure 4. 9—14 Image Figure 5. 15—19 Image Figure 6. 20—45 Image Figure 7. Global 9-valent HPV Vaccine (9vHPV) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global 9-valent HPV Vaccine (9vHPV) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Men Image Figure 10. Women Image Figure 11. Global 9-valent HPV Vaccine (9vHPV) Market Size (US$ Million) & (2021-2032) Figure 12. Global 9-valent HPV Vaccine (9vHPV) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global 9-valent HPV Vaccine (9vHPV) Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global 9-valent HPV Vaccine (9vHPV) Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Type (2021-2032) Figure 19. Global 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Application (2021-2032) Figure 22. North America 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032) Figure 24. North America 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032) Figure 25. North America 9-valent HPV Vaccine (9vHPV) Revenue Share by Country (2021-2032) Figure 26. United States 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032) Figure 31. Europe 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032) Figure 32. Europe 9-valent HPV Vaccine (9vHPV) Revenue Share by Country (2021-2032) Figure 33. Germany 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032) Figure 43. China 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032) Figure 44. Asia 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032) Figure 46. Asia 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032) Figure 47. Asia 9-valent HPV Vaccine (9vHPV) Revenue Share by Region (2021-2032) Figure 48. Japan 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032) Figure 56. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032) Figure 57. SAMEA 9-valent HPV Vaccine (9vHPV) Revenue Share by Country (2021-2032) Figure 58. Brazil 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt 9-valent HPV Vaccine (9vHPV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • 9—14
  • 15—19
  • 20—45
Applications
  • Men
  • Women
Companies covered
  • GSK
  • Merck
  • Beijing Wantai Biology Pharmaceutical Industry Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 9-valent HPV Vaccine (9vHPV) Market by Type
  3. 1.2.1 Global 9-valent HPV Vaccine (9vHPV) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 9—14
  5. 1.2.3 15—19
  6. 1.2.4 20—45
  7. 1.3 9-valent HPV Vaccine (9vHPV) Market by Application
  8. 1.3.1 Global 9-valent HPV Vaccine (9vHPV) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Men
  10. 1.3.3 Women
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 9-valent HPV Vaccine (9vHPV) Market Dynamics
  1. 2.1 9-valent HPV Vaccine (9vHPV) Industry Trends
  2. 2.2 9-valent HPV Vaccine (9vHPV) Industry Drivers
  3. 2.3 9-valent HPV Vaccine (9vHPV) Industry Opportunities and Challenges
  4. 2.4 9-valent HPV Vaccine (9vHPV) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global 9-valent HPV Vaccine (9vHPV) Market Perspective (2021-2032)
  2. 3.2 Global 9-valent HPV Vaccine (9vHPV) Growth Trends by Region
  3. 3.2.1 Global 9-valent HPV Vaccine (9vHPV) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global 9-valent HPV Vaccine (9vHPV) Market Size by Region (2021-2026)
  5. 3.2.3 Global 9-valent HPV Vaccine (9vHPV) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global 9-valent HPV Vaccine (9vHPV) Revenue by Players
  2. 4.1.1 Global 9-valent HPV Vaccine (9vHPV) Revenue by Players (2021-2026)
  3. 4.1.2 Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global 9-valent HPV Vaccine (9vHPV) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global 9-valent HPV Vaccine (9vHPV) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global 9-valent HPV Vaccine (9vHPV) Key Players Headquarters & Area Served
  7. 4.4 Global 9-valent HPV Vaccine (9vHPV) Players, Product Type & Application
  8. 4.5 Global 9-valent HPV Vaccine (9vHPV) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global 9-valent HPV Vaccine (9vHPV) Market CR5 and HHI
  11. 4.6.3 2025 9-valent HPV Vaccine (9vHPV) Tier 1, Tier 2, and Tier 3
5 9-valent HPV Vaccine (9vHPV) Market Size by Type
  1. 5.1 Global 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2032)
  3. 5.3 Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Type (2021-2032)
6 9-valent HPV Vaccine (9vHPV) Market Size by Application
  1. 6.1 Global 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2032)
  3. 6.3 Global 9-valent HPV Vaccine (9vHPV) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK 9-valent HPV Vaccine (9vHPV) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GSK 9-valent HPV Vaccine (9vHPV) Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck 9-valent HPV Vaccine (9vHPV) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck 9-valent HPV Vaccine (9vHPV) Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Beijing Wantai Biology Pharmaceutical Industry Limited
  14. 7.3.1 Beijing Wantai Biology Pharmaceutical Industry Limited Company Information
  15. 7.3.2 Beijing Wantai Biology Pharmaceutical Industry Limited Business Overview
  16. 7.3.3 Beijing Wantai Biology Pharmaceutical Industry Limited 9-valent HPV Vaccine (9vHPV) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Beijing Wantai Biology Pharmaceutical Industry Limited 9-valent HPV Vaccine (9vHPV) Product Portfolio
  18. 7.3.5 Beijing Wantai Biology Pharmaceutical Industry Limited Recent Developments
8 North America
  1. 8.1 North America 9-valent HPV Vaccine (9vHPV) Revenue (2021-2032)
  2. 8.2 North America 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2032)
  3. 8.2.1 North America 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026)
  4. 8.2.2 North America 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032)
  5. 8.3 North America 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032)
  6. 8.4 North America 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2032)
  7. 8.4.1 North America 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026)
  8. 8.4.2 North America 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032)
  9. 8.5 North America 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032)
  10. 8.6 North America 9-valent HPV Vaccine (9vHPV) Revenue by Country
  11. 8.6.1 North America 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021-2026)
  13. 8.6.3 North America 9-valent HPV Vaccine (9vHPV) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe 9-valent HPV Vaccine (9vHPV) Revenue (2021-2032)
  2. 9.2 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2032)
  3. 9.2.1 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026)
  4. 9.2.2 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032)
  5. 9.3 Europe 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032)
  6. 9.4 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2032)
  7. 9.4.1 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026)
  8. 9.4.2 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032)
  9. 9.5 Europe 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032)
  10. 9.6 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Country
  11. 9.6.1 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021-2026)
  13. 9.6.3 Europe 9-valent HPV Vaccine (9vHPV) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China 9-valent HPV Vaccine (9vHPV) Revenue (2021-2032)
  2. 10.2 China 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2032)
  3. 10.2.1 China 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026)
  4. 10.2.2 China 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032)
  5. 10.3 China 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032)
  6. 10.4 China 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2032)
  7. 10.4.1 China 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026)
  8. 10.4.2 China 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032)
  9. 10.5 China 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia 9-valent HPV Vaccine (9vHPV) Revenue (2021-2032)
  2. 11.2 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2032)
  3. 11.2.1 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026)
  4. 11.2.2 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032)
  5. 11.3 Asia 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032)
  6. 11.4 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2032)
  7. 11.4.1 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026)
  8. 11.4.2 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032)
  9. 11.5 Asia 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032)
  10. 11.6 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Country
  11. 11.6.1 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021-2026)
  13. 11.6.3 Asia 9-valent HPV Vaccine (9vHPV) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue (2021-2032)
  2. 12.2 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Type (2027-2032)
  5. 12.3 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Application (2027-2032)
  9. 12.5 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Country
  11. 12.6.1 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA 9-valent HPV Vaccine (9vHPV) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst